Araştırma Makalesi

Detection of the 5HT2C polymorphism in myocardial infarction and cardiovascular event patients

Cilt: 12 Sayı: 2 28 Mayıs 2019
PDF İndir
EN TR

Detection of the 5HT2C polymorphism in myocardial infarction and cardiovascular event patients

Öz

Purpose: Deaths from cardiovascular (CV) disease are prevalent worldwide. Genetics, environment, nutritional habits, and lifestyle are major factors in the etiology of Coronary artery disease (CAD). Certain genes (that play roles in lipid, homocysteine, glucose metabolism, renin-angiotensin, fibrinolytic, and inflammation systems) have been found in association with CAD by genome-wide association studies. The present genes are not important for direct and independent prediction. A recent study on the rs6318 polymorphism of the serotonin receptor 2C (5HT2C) gene in the prediction of CAD and myocardial infarction (MI) can meet the expected criteria. The aim of our study is to determine the predictive and risk alleles of the rs6318 polymorphism of the 5HT2C gene by comparing healthy subjects with patients diagnosed with MI and CAD.

Materials and Methods: The study consisted of two groups: 142 patients and 100 controls. DNA was isolated from venous blood and "melting curve genotyping" analysis was performed.

Results: GC genotype was 4.9% in the case group and 27% in the control group. The GC genotype is protective against CV disease (p=0.01). In addition, the observation that no GC genotyped subjects were diagnosed with MI suggests that the GC genotype is protective for MI in our study. Also, among cases with MI, it was found that only 1 patient (0.9%) was CC homozygote, while there were 12 patients (11%) that were C hemizygotes. 

Conclusion: The results suggest that the C allele has a protective effect against CV diseases, although no clear statistical significance is found.

Anahtar Kelimeler

Kaynakça

  1. Mathers CD, Loncar D, Boreham J, Thun M, Heath J, Doll R. Projections of Global Mortality and Burden of Disease from 2002 to 2030. Samet J, editor. PLoS Med. World Bank; 2006;3[11]:e442. Available from: http://dx.plos.org/10.1371/journal.pmed.0030442
  2. WHO. Global atlas on cardiovascular disease prevention and control. World Health Organization. Geneva, World Health Organization; 2017. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/
  3. TÜİK. Türkiye İstatistik Kurumu, Ölüm Nedeni İstatistikleri, 2016. Türkiye İstatistik Kurumu. 2017. Available from: http://www.tuik.gov.tr/PreHaberBultenleri.do?id=24572
  4. Chico TJ, Milo M, Crossman DC. The genetics of cardiovascular disease: new insights from emerging approaches. J Pathol 2009;220[2]:186–97.
  5. Delles C, Mcbride MW, Padmanabhan S, Dominiczak AF. The genetics of cardiovascular disease. Trends Endocrinol Metab 2008;19[9]:309–16.
  6. Abbate R, Sticchi E, Fatini C. Study at Molecular and Clinical Level of Chronic, Degenerative and Neoplastic Diseases to Develop Novel Therapies. Clin Cases Miner Bone Metab. 2008;5[1]:63–6.
  7. Marrugat J, D’Agostino R, Sullivan L, Elosua R, Wilson P, Ordovas J, et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health 2003;57[8]:634–8.
  8. Janssens ACJW, Aulchenko YS, Elefante S, Borsboom GJJM, Steyerberg EW, van Duijn CM. Predictive testing for complex diseases using multiple genes: Fact or fiction? Genet Med. 2006;8[7]:395–400.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Klinik Tıp Bilimleri

Bölüm

Araştırma Makalesi

Yazarlar

Buket Er Urgancı Bu kişi benim
Türkiye

Dursun Dursunoğlu Bu kişi benim
Türkiye

Asuman Kaftan Bu kişi benim
Türkiye

Yayımlanma Tarihi

28 Mayıs 2019

Gönderilme Tarihi

13 Kasım 2018

Kabul Tarihi

8 Şubat 2019

Yayımlandığı Sayı

Yıl 2019 Cilt: 12 Sayı: 2

Kaynak Göster

APA
Açıkbaş, İ., Er Urgancı, B., Dursunoğlu, D., & Kaftan, A. (2019). Detection of the 5HT2C polymorphism in myocardial infarction and cardiovascular event patients. Pamukkale Medical Journal, 12(2), 243-249. https://doi.org/10.31362/patd.482444
AMA
1.Açıkbaş İ, Er Urgancı B, Dursunoğlu D, Kaftan A. Detection of the 5HT2C polymorphism in myocardial infarction and cardiovascular event patients. Pam Tıp Derg. 2019;12(2):243-249. doi:10.31362/patd.482444
Chicago
Açıkbaş, İbrahim, Buket Er Urgancı, Dursun Dursunoğlu, ve Asuman Kaftan. 2019. “Detection of the 5HT2C polymorphism in myocardial infarction and cardiovascular event patients”. Pamukkale Medical Journal 12 (2): 243-49. https://doi.org/10.31362/patd.482444.
EndNote
Açıkbaş İ, Er Urgancı B, Dursunoğlu D, Kaftan A (01 Mayıs 2019) Detection of the 5HT2C polymorphism in myocardial infarction and cardiovascular event patients. Pamukkale Medical Journal 12 2 243–249.
IEEE
[1]İ. Açıkbaş, B. Er Urgancı, D. Dursunoğlu, ve A. Kaftan, “Detection of the 5HT2C polymorphism in myocardial infarction and cardiovascular event patients”, Pam Tıp Derg, c. 12, sy 2, ss. 243–249, May. 2019, doi: 10.31362/patd.482444.
ISNAD
Açıkbaş, İbrahim - Er Urgancı, Buket - Dursunoğlu, Dursun - Kaftan, Asuman. “Detection of the 5HT2C polymorphism in myocardial infarction and cardiovascular event patients”. Pamukkale Medical Journal 12/2 (01 Mayıs 2019): 243-249. https://doi.org/10.31362/patd.482444.
JAMA
1.Açıkbaş İ, Er Urgancı B, Dursunoğlu D, Kaftan A. Detection of the 5HT2C polymorphism in myocardial infarction and cardiovascular event patients. Pam Tıp Derg. 2019;12:243–249.
MLA
Açıkbaş, İbrahim, vd. “Detection of the 5HT2C polymorphism in myocardial infarction and cardiovascular event patients”. Pamukkale Medical Journal, c. 12, sy 2, Mayıs 2019, ss. 243-9, doi:10.31362/patd.482444.
Vancouver
1.İbrahim Açıkbaş, Buket Er Urgancı, Dursun Dursunoğlu, Asuman Kaftan. Detection of the 5HT2C polymorphism in myocardial infarction and cardiovascular event patients. Pam Tıp Derg. 01 Mayıs 2019;12(2):243-9. doi:10.31362/patd.482444
Creative Commons Lisansı
Pamukkale Tıp Dergisi, Creative Commons Atıf-GayriTicari 4.0 Uluslararası Lisansı ile lisanslanmıştır